Related Experiment Video
Updated: Jun 17, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line
Sang-Lin Li1, Feng Ye, Wei-Jun Cai
1Key Laboratory of Molecular Biology for Infectious Diseases of Ministry of Education of China, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Abstract:
In order to understand the molecular mechanisms of multidrug resistance (MDR) in ovarian cancer, we employed the proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by LC-MS/MS, using the cisplatin-resistant COC1/DDP cell line and its parental COC1 cell line as a model. A total number of 28 proteins differentially expressed were identified, and then the differential expression levels of partially identified proteins were confirmed by Western blot analysis and/or real-time RT-PCR. Furthermore, the association of PKM2 and HSPD1, two differentially expressed proteins, with MDR were analyzed, and the results showed that they could contribute considerably to the cisplatin resistance in ovarian cancer cell. The differential expression proteins could be classified into eight categories based on their functions, that is, calcium binding proteins, chaperones, extracellular matrix, proteins involved in drug detoxification or repair of DNA damage, metabolic enzymes, transcription factor, proteins related to cellular structure and proteins relative to signal transduction. These data will be valuable for further study of the mechanisms of MDR in the ovarian cancer.
Insights
This study uncovers key proteins contributing to multidrug resistance (MDR) in ovarian cancer. Understanding these molecular mechanisms, like PKM2 and HSPD1, can help develop new treatments for cisplatin resistance.
Area of Science:
- Proteomics
- Molecular Biology
- Oncology
Background:
- Ovarian cancer frequently develops multidrug resistance (MDR), limiting treatment efficacy.
- Understanding the molecular underpinnings of MDR is crucial for improving patient outcomes.
Purpose of the Study:
- To identify differentially expressed proteins associated with cisplatin resistance in ovarian cancer.
- To elucidate the molecular mechanisms driving multidrug resistance in ovarian cancer cells.
Main Methods:
- Proteomic analysis using isobaric tags for relative and absolute quantification (iTRAQ) and LC-MS/MS.
- Validation of protein expression using Western blot and real-time RT-PCR.
- Functional association analysis of identified proteins with cisplatin resistance.
Main Results:
- Identified 28 differentially expressed proteins between cisplatin-resistant (COC1/DDP) and parental (COC1) ovarian cancer cells.
- Confirmed differential expression of selected proteins, including PKM2 and HSPD1.
- Demonstrated that PKM2 and HSPD1 contribute significantly to cisplatin resistance in ovarian cancer cells.
Conclusions:
- The identified proteins, categorized by function, offer insights into MDR mechanisms in ovarian cancer.
- PKM2 and HSPD1 are potential therapeutic targets for overcoming cisplatin resistance.
- These findings provide a foundation for further research into ovarian cancer MDR.
